Dihydroergotamine Mesylate Spray
Product Images NDC 68682-357

5 FDA label images from Oceanside Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate (NDC 68682-357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oceanside Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1

Figure 1
A line graph showing the estimated probability of patient response over four hours after a single 2 mg dose of Dihydroergotamine Mesylate nasal spray compared to placebo. Time from first dose (hours) is on the x-axis, and estimated response probability (%) is on the y-axis. The drug shows a higher response probability than placebo across all time points.*
FDA Label Image

Figure 2

Figure 2
A line graph showing the estimated probability of a patient responding to Dihydroergotamine Mesylate nasal spray versus placebo over four hours after dosing. The y-axis represents probability response percentage, and the x-axis shows time in hours. Dihydroergotamine Mesylate response increases steadily, surpassing placebo across the time points.*
FDA Label Image

Figure 3

Figure 3
A line graph titled 'Estimated Probability of Patients Using Additional Treatments for Migraine Over the 24 Hours Following Either Dihydroergotamine Mesylate Nasal Spray 2 mg (or placebo).' The graph shows the estimated probability of analgesic use on the vertical axis (0-100%) versus hours after first spray on the horizontal axis (0-24 hours). Two lines are plotted: one for Dihydroergotamine Mesylate and one for placebo, comparing the probability of patients using additional migraine treatments over time.*
FDA Label Image

Image 01

Image 01
Packaging label for Dihydroergotamine Mesylate nasal spray 4 mg/mL by Oceanside Pharmaceuticals. The kit contains 8 dihydroergotamine mesylate vials and 8 nasal sprayers. The label includes administration instructions, storage information, and warnings that the product is for nasal use only, not for injection. Distributed by Oceanside Pharmaceuticals, manufactured by Mipharm S.p.A., Italy.*
FDA Label Image

Chemical Structure (Migranal 01)

Chemical Structure (Migranal 01)
Chemical structure of dihydroergotamine mesylate, showing the molecular formula C33H37N5O5•CH4O3S and a molecular weight of 679.80.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.